Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Katarzyna Zajda
Observed names:
K Zajda,
K. Zajda
Institution:
The Maria Sklodowska-Curie National Research Institute of Oncology
Observed institutions:
Centrum Onkologii,
The Maria Sklodowska-Curie National Research Institute of Oncology
ORCID:
0000-0002-0052-132X
Observed ORCID:
0000-0002-0052-132X
OpenAlex ID:
A5058280907
CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer
2011
·
Lidia Karabon
, Edyta Pawlak
, et al.
·
Human Immunology
·
52
Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy
2023
·
Magdalena Zaborowska-Szmit
, Sebastian Szmit
, et al.
·
Cancers
·
18
PDF
Venous thromboembolism is associated with increased all-cause mortality in ALK-positive non-small cell lung cancer
2024
·
Magdalena Zaborowska-Szmit
, Sebastian Szmit
, et al.
·
Cardio-Oncology
·
10
PDF
Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice
2023
·
Magdalena Knetki-Wróblewska
, Sylwia Tabor
, et al.
·
Journal of Clinical Medicine
·
9
PDF
Recovery of dendritic cell counts and function in peripheral blood of cancer patients after chemotherapy
2002
·
Sergiusz Markowicz
, Jan Walewski
, et al.
·
Cytokines Cellular & Molecular Therapy
·
9
Performance-Status Deterioration during Sequential Chemo-Radiotherapy as a Predictive Factor in Locally Advanced Non-Small Cell Lung Cancer
2023
·
Marta Olszyna-Serementa
, Magdalena Zaborowska-Szmit
, et al.
·
Current Oncology
·
4
PDF
Epoetin delta in the management of anaemia in cancer patients
2007
·
K. Zajda
, M. Krzakowski
·
Journal of Clinical Oncology
·
3
Gefitinib in Patients with Advanced Non-small-Cell Lung Cancer
2012
·
Magdalena Knetki-Wróblewska
, Dariusz Kowalski
, et al.
·
Advances in respiratory medicine
·
2
PDF
Cardiovascular biomarker phenotype associated with immune checkpoint inhibitor therapy in patients with non-small cell lung cancer: an exploratory blood transcriptome study
2026
·
Joanna Ziemska-Legięcka
, Natalia Żeber-Lubecka
, et al.
·
Frontiers in Immunology
PDF
EP12.11: Real-World Outcomes of Polish Patients With ALK-Positive NSCLC Treated With Brigatinib: 1-Year Results (ENTIRETY Study)
2026
·
K. Stencel
, G. Czyżewicz
, et al.
·
Journal of Thoracic Oncology
557eP Advanced thymic squamous cell carcinoma: Results of palliative systemic treatment in long-term follow-up
2026
·
M. Knetki-Wroblewska
, D.M. Kowalski
, et al.
·
ESMO Open
282P Three decades of experience in squamous thymic carcinoma: Treatment outcomes and challenges in a rare malignancy
2026
·
M. Knetki-Wroblewska
, D.M. Kowalski
, et al.
·
ESMO rare cancers.
PDF
Real-world baseline characteristics and diagnostic path of Polish patients with ALK-positive NSCLC eligible for brigatinib treatment: Interim results from the ENTIRETY study.
2025
·
Katarzyna Magdalena Stencel
, Grzegorz Czyżewicz
, et al.
·
Journal of Clinical Oncology
PDF
63P Inflammatory indexes and treatment response as correlates of pembrolizumab effectiveness in patients with PD-L1≥50%: Data from the real-life practice
2023
·
M. Knetki-Wroblewska
, S. Tabor
, et al.
·
Journal of Thoracic Oncology
PDF
1040P Nivolumab or atezolizumab in the second-line treatment of advanced non-small-cell lung cancer? Prognostic index based on real-world data
2022
·
M. Knetki-Wroblewska
, A. Płużański
, et al.
·
Annals of Oncology
P78.08 Prediction of Pembrolizumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Based on Experience From Expanded Access Program in Poland
2021
·
M. Knetki-Wróblewska
, D.M. Kowalski
, et al.
·
Journal of Thoracic Oncology
Randomized, double-blind, placebo-controlled trial of evofosfamide (Evo) and pemetrexed (Pem) in advanced non-squamous non-small cell lung cancer (n-s NSCLC).
2016
·
Tibor Csõszi
, Jonathan Wade Goldman
, et al.
·
Journal of Clinical Oncology
Characteristic and management of lung cancer as a secondary malignancy.
2012
·
Adam Pluzanski
, Pawel Badurak
, et al.
·
Journal of Clinical Oncology
Intensity-modulated radiation therapy as adjuvant treatment for local advanced malignant mesothelioma after pleuropneumonectomy – report of two cases
2011
·
Dariusz Kowalski
, Kinga Winiarczyk
, et al.
·
Kardiochirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery
Oral vinorelbine (NVBo) at 3-weekly flat-dose intakes (FDI) as single agent or with cisplatin (CDDP) concomitantly with thoracic radiotherapy (RT) in stage III NSCLC: Escalation-dose phase I trial results.
2011
·
D. M. Kowalski
, M. J. Krzakowski
, et al.
·
Journal of Clinical Oncology
Combined treatment of patients with incompletely resected invasive thymoma: A retrospective analysis
2007
·
D. M. Kowalski
, A. Janowicz-Zebrowska
, et al.
·
Journal of Clinical Oncology
Efficacy and tolerability of gemcytabine plus docetaxel in patients with locally advanced or metastatic adenocarcinoma of the lung
2006
·
M. Krzakowski
, D. M. Kowalski
, et al.
·
Journal of Clinical Oncology
O-178 Morbidity and mortality of pneumonectomy for lung cancer:Neoadjuvant chemotherapy does not increase the risk of postoperative complications
2005
·
M. Glogowski
, M. Zmijewski
, et al.
·
Lung Cancer
49 Efficacy and tolerability of gemcitabine (GCB) plus docetaxel (DXL) in patients with locally advanced or metastatic adenocarcinoma (AC) of the lung
2005
·
D. Kowalski
, K. Zajda
, et al.
·
Lung Cancer
P-593 Preliminary results of phase II study of daily paclitaxel andcarboplatin administered concurrently with chest irradiation in stage III unresectable NSCLC
2005
·
M. Wierzchowski
, T. Denisso
, et al.
·
Lung Cancer
Show more works
View as search
Works count:
32
Citation count:
107
H-index:
5
I10-index:
3
Year
Topic
Type